Van Lanschot Kempen Investment Management N.V. Grows Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Van Lanschot Kempen Investment Management N.V. lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 43.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 309,975 shares of the medical research company’s stock after purchasing an additional 93,425 shares during the quarter. Thermo Fisher Scientific comprises about 1.6% of Van Lanschot Kempen Investment Management N.V.’s investment portfolio, making the stock its 14th biggest position. Van Lanschot Kempen Investment Management N.V. owned about 0.08% of Thermo Fisher Scientific worth $161,258,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in TMO. Howard Capital Management Group LLC boosted its holdings in shares of Thermo Fisher Scientific by 0.5% in the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company’s stock valued at $33,759,000 after purchasing an additional 286 shares during the last quarter. Principal Financial Group Inc. increased its stake in Thermo Fisher Scientific by 22.1% during the third quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company’s stock worth $771,876,000 after acquiring an additional 225,568 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $638,000. Anchor Investment Management LLC grew its holdings in shares of Thermo Fisher Scientific by 1.7% during the 3rd quarter. Anchor Investment Management LLC now owns 11,366 shares of the medical research company’s stock worth $7,031,000 after purchasing an additional 195 shares during the period. Finally, World Investment Advisors LLC raised its holdings in Thermo Fisher Scientific by 3.8% in the third quarter. World Investment Advisors LLC now owns 15,088 shares of the medical research company’s stock valued at $9,333,000 after buying an additional 548 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the transaction, the chief executive officer now directly owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares of the company’s stock, valued at $5,759,736.32. The trade was a 25.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock valued at $13,106,062 in the last three months. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Down 2.4 %

NYSE TMO opened at $426.11 on Monday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company has a 50-day simple moving average of $497.67 and a 200-day simple moving average of $532.62. The firm has a market capitalization of $160.85 billion, a PE ratio of 25.78, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific Inc. has a one year low of $409.85 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date was Friday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s payout ratio is 10.41%.

Analyst Upgrades and Downgrades

TMO has been the topic of several recent research reports. Citigroup reduced their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Barclays decreased their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. UBS Group boosted their price target on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Finally, Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $642.67.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.